Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Switzerland
Thailand
UK
Ukraine
The links provided redirect to third-party websites that require a subscription/registration to access publications.
Scientific publications
News from our pipeline
- Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
- Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
- Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
- Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
- Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
- Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
- Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
